The patient must have signed and dated an institutional review board (IRB)-approved consent form that conforms to federal and institutional guidelines;
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination;
All of the following staging criteria (according to the 7th edition of the American Joint Committee on Cancer [AJCC] Cancer Staging Manual) must be met: *By pathologic evaluation, primary tumor must be pT1-3
*By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN2b, pN3a, or pN3b
*If pN0, tumor must be > 3.0 cm;
The tumor must have been determined to be human epidermal growth factor receptor 2 (HER2)-negative as follows: *Immunohistochemistry (IHC) 0-1+ or *IHC 2+ and in situ hybridization (ISH) non-amplified with a ratio of HER2 to centromere enumerator probe 17 (CEP17) < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells or *ISH non-amplified with a ratio of HER2 to CEP17 < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells;
The tumor must have been determined to be estrogen receptor (ER)-and progesterone receptor (PgR)-negative assessed by current American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Patients with < 1% ER and PgR staining by IHC are considered negative;
The patient must have undergone either a mastectomy (total, skin-sparing, or nipple-sparing) or lumpectomy

T4 tumors including inflammatory breast cancer;
Definitive clinical or radiologic evidence of metastatic disease. Required imaging studies must have been performed within 90 days prior to randomization;
Synchronous or previous contralateral invasive breast cancer (patients with synchronous and/or previous contralateral DCIS or LCIS are eligible);
Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS (patients with synchronous or previous ipsilateral LCIS are eligible);
History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization;
Previous therapy with anthracyclines or taxanes for any malignancy;
Chemotherapy administered for the currently diagnosed breast cancer prior to randomization;
Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy. Patients are eligible if these medications are discontinued prior to randomization;
Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens. This includes but is not confined to: *Active cardiac disease *History of cardiac disease;
Uncontrolled hypertension defined as sustained systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg (patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria);
Active hepatitis B or hepatitis C with abnormal liver function tests

• Alkylating Agents

• Adenocarcinoma

• Antibiotics, Antineoplastic

• Antimitotic Agents

• Antineoplastic Agents

• Antineoplastic Agents, Alkylating

• Antineoplastic Agents, Phytogenic

• Antirheumatic Agents

• BR003

• Breast Diseases

• Breast Neoplasms

• Carboplatin

• Carcinoma

• Cyclophosphamide

• Doxorubicin

• Enzyme Inhibitors

• Immunologic Factors

• Immunosuppressive Agents

• Liposomal doxorubicin

• Mitosis Modulators

• Molecular Mechanisms of Pharmacological Action

• Myeloablative Agonists

• Neoplasms

• Neoplasms by Histologic Type

• Neoplasms by Site

• Neoplasms, Glandular and Epithelial

• Paclitaxel

• Pharmacologic Actions

• Physiological Effects of Drugs

• Skin Diseases

• Triple Negative Breast Neoplasms

• Oncology (Adult)

• NRG Oncology